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Editorial  17 
Although hepatitis E virus (HEV) is a much understudied pathogen, it is one of the most important 18 
causes of acute hepatitis worldwide. Based on calculations for genotypes 1 and 2, an annual 19 
incidence of 20 million HEV infections resulting in about 70.000 deaths has been estimated [1]. These 20 
two genotypes are endemic in developing countries and cause large-scale water-borne outbreaks [2], 21 
such as the very recent outbreak in Nepal (www.promedmail.org; archive number: 22 
20140509.2461705). A hallmark for such outbreaks is the high morbidity and mortality observed in 23 
pregnant women, with fatality rates up to 25%. The underlying pathogenesis for this particular 24 
vulnerability of pregnant woman is only very poorly understood, [1-3] although progesterone 25 
receptor polymorphisms may play a role [4]. Genotypes 3 and 4 are, by contrast, zoonotic pathogens 26 
that are frequently detected in commercial pig herds, but also in wild boar and deer [2,3]. The 27 
consumption of un- or undercooked pork is, as consequence, a major risk factor for contracting 28 
hepatitis E. Accordingly, the south of France is considered to be a hyperendemic region because of 29 
the popularity of local delicacies, such as figatellu, that are prepared with raw pork [3,5]. 30 
In general, most HEV infections are asymptomatic and most symptomatic infections resolve 31 
spontaneously [2,3]. Nevertheless, some patients may evolve to fulminant hepatitis, explaining the 32 
reported overall mortality rates of 0.5-4% [3]. Since 2008, it is known that hepatitis E can evolve to 33 
chronicity in immunocompromised patients [6]. Chronic hepatitis E has since been observed in HIV 34 
patients and leukemia patients undergoing chemotherapy, but most cases are organ transplant 35 
recipients receiving immunosuppressive treatment [2]. About 30% of chronic infections in the latter 36 
group can be resolved by reducing the level of immunosuppression [7]. Commonly used 37 
immunosuppressive drugs in the transplant setting are corticosteroids, mycophenolate mofetil 38 
(MMP), calcineurin inhibitors (cyclosporin A and tacrolimus) and the mTOR (mammalian target of 39 
rapamycin) inhibitors such as rapamycin and everolimus. In this issue of the Journal of Hepatology, 40 
Zhou et al. demonstrate that the latter two drugs promote in vitro HEV replication through inhibition 41 
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of mTOR [8]. Thorough studies of the involved signaling pathways reveal that mTOR is part of an 42 
antiviral signaling pathway that inhibits HEV replication. This antiviral activity is mediated through 43 
the eIF4E-binding protein 1 (4E-BP1) directly downstream of mTOR. 44 
In another recent study by the same authors, the in vitro effect of other immunosuppressive drugs 45 
on HEV replication was reported [9]. While steroids were shown to have no effect on viral 46 
replication, the calcineurin targeting drugs cyclosporin A and tacrolimus resulted in a pronounced 47 
proviral effect which was shown to be mediated by the inhibition of cyclophilins A and B. By contrast 48 
mycophenolic acid (the active component of mycophenolate mofetil, MMP) was shown to be an 49 
inhibitor of in vitro HEV replication [9,10]. This antiviral effect may be in line with a clinical 50 
observation that the use of MMP was associated with HEV clearance [11]. It should be noted though 51 
that this observation was based on a small number of patients. 52 
These findings raise the question whether the immunosuppressive drug scheme should be adapted 53 
for patients with chronic hepatitis E. Should calcineurin and mTOR inhibitors be avoided and MMP 54 
(and possibly steroids) be preferred if a patient in need of immunosuppression has been shown to be 55 
HEV positive? Should such preferences be extended to non-infected patients who are at risk of 56 
contracting chronic hepatitis E (such as for example pig farmers)? One important caveat is that such 57 
recommendations would be solely based on in vitro findings that possibly do not take all aspects of 58 
hepatitis E pathogenesis into account. For instance, the in vitro anti-HEV activity of mycophenolic 59 
acid is mediated by an efficient depletion of intracellular GTP pools in cell cultures; an antiviral effect 60 
that can be easily reversed upon exogenously addition of guanosine [10]. It is however questionable 61 
whether such strong depletion of GTP pools by MMF is at all possible in the human liver [12]. Even if 62 
MMF would be able to deplete GTP pools in the liver to levels that may be sufficiently low to impact 63 
HEV replication, the virus may, in an immunocompromised environment, not necessarily be much 64 
limited in its replication. Mycophenolic acid inhibits also efficiently and completely the in vitro 65 
replication of a number of flaviviruses [13]. Yet in a murine model for flavivirus infection, we did not 66 
4 
 
observe any protective activity of MMF (our unpublished data). Similarly, addition of MMF to 67 
interferon for the treatment of interferon-non-responsive chronic hepatitis C patients proved 68 
ineffective in a clinical trial [14]. It will thus be important to explore the impact of these different 69 
immunosuppressive drugs on HEV replication in (a) relevant infection model(s) in animals. HEV 70 
replication was recently demonstrated in uPA/SCID mice of which the diseased liver had been 71 
repopulated with human hepatocytes [15]. This, and perhaps other, yet to be developed models, 72 
may be instrumental to demonstrate the differential (anti- and proviral) effects of the different 73 
immunosuppressive drugs. Retrospective studies on cohorts of chronic hepatitis E patients may allow 74 
to unveil whether a link exists between the clinical outcome and the choice of 75 
immunosuppressant(s). The low number of (reported) cases of chronic hepatitis E may complicate 76 
such exercise; yet given the recent increase in diagnosed cases, such studies may become feasible in 77 
the future. 78 
One may put different hypotheses forward to explain the antiviral defense mechanism mediated by 79 
mTOR and downstream 4E-BP1. The protein 4E-BP1 is known to be a translational repressor, by 80 
interacting with the essential eukaryotic initiation factor 4E (eIF4E), mRNA translation is inhibited 81 
[16]. mTOR is known to phosphorylate and, thus to deactivate 4E-BP1, thereby releasing eIF4E which 82 
then initiates mRNA translation. More specifically, 4E-BP1 has important regulatory functions in the 83 
interferon (IFN) response [17]. Cells knocked-out for 4E-BP1 are remarkably resistant to viral 84 
infection because of a decreased threshold for IFN production [18]. This phenomenon is mediated by 85 
increased mRNA translation of IFN regulatory factor 7 (Irf7) which is normally suppressed by 4E-BP1. 86 
A similar mechanism may apply to the observed increase in HEV replication caused by rapamycin and 87 
everolimus. Indeed following inhibition of mTOR activity, 4E-BP1 may not be phosphorylated and 88 
thus remain associated with eIF4E. In this way, translation of Irf7 or other factors would be inhibited, 89 
which may in turn result in a decreased IFN response and thus overall increased HEV replication. 90 
Other factors may of course be involved as well and alternative mechanisms may apply. 91 
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Most transplant patients with chronic hepatitis E that do not clear the virus by reducing 92 
immunosuppression are treated with an extended course of ribavirin [19]. Although this therapy is 93 
mostly effective, cases of treatment failure have been reported [20]. Moreover, long courses of 94 
ribavirin often result in side effects, including anemia. Modulation of the immunosuppressive drug 95 
scheme could be a very useful strategy to improve response rates to ribavirin, decrease the number 96 
of patients in need of ribavirin treatment and shorten the treatment time altogether. Today potent 97 
antiviral drugs are available for the treatment of infections with herpesviruses, the human 98 
immunodeficiency virus, the hepatitis B and C viruses and to a lesser extent influenza. Viral 99 
polymerase inhibitors (whether targeting DNA polymerases, reverse transcriptases or RNA 100 
dependent RNA polymerase) have been shown to be excellent targets for inhibition of viral 101 
replication [21]. Using a combination of highly potent and well tolerated antivirals, including 102 
nucleoside polymerase inhibitors, several studies recently reported a sustained virological response 103 
cure in >95 % of patients chronically infected with the hepatitis C virus [22]. This latter virus is, akin 104 
to HEV, a +ssRNA virus and encodes for several proteins (including a RNA dependent RNA 105 
polymerase) that may be good targets for pharmacological inhibition of viral replication [23]. In fact, 106 
it has been shown that some HCV nucleoside polymerase inhibitors (in particular the 2’C methyl 107 
series) inhibit the replication of yet other +ssRNA viruses including, but not limited to flaviviruses, 108 
enteroviruses and noroviruses [24]. It remains to be studied whether (some of the) HCV nucleoside 109 
polymerase inhibitors that have, or will reach the market, also inhibit HEV replication. In such case, 110 
they may be used (even off-label) either alone, or in combination with ribavirin, for the control of 111 
HEV infections. If such combination treatment would be sufficiently potent, there may no longer be a 112 
need to reduce immunosuppression to control chronic HEV infection in immunodeficient patients.  113 
In conclusion, the work by Zhou and colleagues reported in the current issue highlights the potential 114 
importance of choosing the most appropriate immunosuppressant for use in patients with chronic 115 
hepatitis E. Confirmation of the observed in vitro effects in a suitable animal model for hepatitis E is 116 
awaited. Retrospective analyses (and if possible prospective studies) of immunosuppressive regimens 117 
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in chronic hepatitis E patients will also help to understand the potential effect of immunosuppressive 118 
drugs on HEV replication in the infected patient. 119 
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